INTRODUCTION
The incidence of echinococcosis in European countries varies from 0.1 to 10 cases per 100 000 residents (Eiermann et al., 1998; Lukmanova et al., 2011; Mosayebi et al., 2013) . The number of cases of echinococcosis diagnosed for the first time is rather high in Latvia as well, despite a comparatively low population size. The location of Latvia next to endemic regions for this zoonotic disease, for example, Russia, Belarus, Poland is also an important factor (Eiermann et al., 1998 , Lukmanova et al., 2011 ; however, no targeted studies on the incidence, risk factors, diagnostics and therapy have been conducted particularly in our country. Data on the quality of life of patients in cases where radical surgical extraction of the parasite was impossible, and on the number of years of medication therapy required, are also lacking.
The development of cystic, as well as alveolar echinococcosis is associated with individual factors of the host organism, as well as immunological reactions. It is known that the susceptibility in humans varies, as there are moresusceptible individuals and non-susceptible or resistant individuals. This is possibly connected with the major histocompatibility complex (MHC) system, which is directly involved in adaptive immune response formation. Since T Windows, Version 22.0 , to evaluate the risk of developing the disease in an individual having a particular HLA genotype. In the case of cystic echinococcosis a more severe course of a disease can be anticipated in the presence of HLA-DRB1 alleles *17:01 and *07:01, -DQB1 *03:02, and *03:01, -DQA1*04:01 and haplotypes HLA-DRB1*04:01/-DQB1*03:01/ -DQA1*03:01, HLADRB1*11:01/ -DQB1*03:01 /-DQA1*05:01. However, in the group with alveolar echinococcosis it was associated with the HLA-DRB1 alleles *17:01 and *07:01, -DQB1 *05:01 and haplotypes HLA-DRB1*17:01/-DQB1*02:01-2/-DQA1*01:01, HLA-DRB1*11:01/ -DQB1*03:01/-DQA1*01:03 and HLA-DRB1*11:01/-DQB1*03:01/-DQA1*03:01. HLA-DRB1*15:01/-DQÂ1*06:02-8/-DQA1*05:01 and HLA-DRB1*13:01/-DQB1*02:01-2/-DQA1 cells recognise only fragmented antigens displayed on cell surfaces, antigen processing must occur before the antigen fragment, bound to the MHC, is transported to the surface of the cell, a process known as presentation, where it can be recognised by a T cell receptor. Antigen presentation describes a vital immune process that is essential for T cell immune response triggering. MHC-II molecules are responsible for the presentation of peptides to T-lymphocytes, which initiate the response of different immune system cells. HLA-DRB1/-DQA1/-DQB1 are the most polymorphic of the HLA class II genes and therefore can be used for individual identification. According to literature data, there are alleles of HLA that are associated with increased risk of developing a disease and alleles that are associated with decreased risk of the progress of the disease (Mosayebi et al., 2013) .
The aim of this study was to assess the relationship between HLA Class II alleles in two groups of patients in Latvia: patients with cystic and alveolar echinococcosis. The study included 37 patients from the Rîga East Clinical University Hospital with echinococcosis (29 patients with cystic echinococcosis and eight patients with alveolar echinococcosis) and 100 healthy control persons without echinococcosis. HLA Class II allele genotyping was performed using Real-time polymerase chain reaction-sequence specific primer (RT-PCR-SSP). The odds ratios (OR), with 95% confidence intervals (95% CI), were calculated using statistical analysis performed with IBM SPSS Statistics for
Review of the conducted research on alveolar echinococcosis presents various results. The data of a study conducted in Germany suggest that HLA-DRB1*11 is associated with decreased risk of developing alveolar echinococcosis, while HLA-DQB1*09:01 with faster progression of the disease (Eiermann et al., 1998) . However, in accordance with research conducted in China, HLA-DRB1*04:0x is associated with increased susceptibility, while HLA-DRB1*07:01 with resistance (Mosayebi et al., 2013) . A study of the Alaskan population showed that HLA-DRB1*09:01 and HLA-DRB1*16:01, *16:02 are associated with elevated susceptibility to disease (Mosayebi et al., 2013) . In a study conducted in 1998 in Europe, the HLA-DRB1*11 allele group was associated with reduced risk of disease development, while HLA-DQB1*02 was more frequently detected in patients with a progressive course of the disease (Aydinli et al., 2007) . The data of a Turkish study showed that allele groups HLA-DRB1*15, HLA-DQB1*02, *06, *07 were most commonly detected in patients, and that HLA-DQB1*02, *06, *07 was more frequently detected in patients with a complicated course of the disease (Aydinli et al., 2007) .
The review of research results dealing with cystic echinococcosis also presents varying results. Data from a study of cystic echinococcosis conducted in Iran showed that HLA-DQB1*03 and HLA-DRB1*11 were associated with decreased risk of the development of cystic echinococcosis (Mosayebi et al., 2013) . A study on children in Russia demonstrated that HLA-DRB1*07, -DQB1*09, and -DQB1*02 were associated with elevated risk of the progression of the disease and HLA-DQB1*02 and -DRB1*03 with a higher risk of developing a complicated condition (superinfection of the cyst content with bacterial pathogens) (Lukmanova et al., 2011) . Data from Lebanon showed that HLA-B*14 and -DRB1*01 alleles were associated with lower risk of contracting the disease, while HLA-B*35 -with high risk; the researchers noted that their results were similar to those from Russia (Chakhtoura et al., 2007) . In the Saudi Arabia population, HLA-DR16 and HLA-DR7 alleles were associated with a higher risk of contracting the disease, while HLA-DR1 and HLA-DR10 alleles ensured resistance (Hussein et al., 2012) . In Yemen, the HLA-DR16 allele was associated with increased risk of getting infected, and HLA-DR1, -DR8 and -DR52 alleles with decreased risk (AlGhoury et al., 2010 ). An Egyptian study also linked HLA-DR3 with increased risk of developing a complicated course of the disease (Azab et al., 2004) . A Turkish study in a child population showed that HLA-DR15 and HLA-B44 were associated with the development of the disease, HLA-B18 and HLA-DR1 with resistance, and HLA-DR11 with a high probability of recovery (Yalcin et al., 2010) . Taking into account that antigen presentation by HLA II molecules is an inductor of specific immune response (Janeway et al., 2001; Male et al., 2013) , it is important, and the aim of this study was to assess the relationship between HLA Class II alleles in two groups of patients in Latvia: patients with cystic and alveolar echinococcosis. This has not been investigated in many previous studies in European countries and also in Latvia.
MATERIALS AND METHODS
Patient group. The study involved 144 patients with echinococcosis in the medical records available at the Rîga East Clinical University Hospital for the time period from 1 January 1999 to 1 February 2015. During selection, 28 patients were not included in the study, because the diagnosis could not be considered to be verified in the presence of positive serology analyses alone, because cross-reaction with other flatworm parasites was possible. Also, other patients were excluded from the study group, because the finding of a simple cyst (radiologically no signs typical of echinococcosis were found) in the liver could not be deemed to be echinococcosis, and furthermore, it is not confirmed by serological analyses. Thus, a total of 116 patients were selected for further analysis.
A total of 37 patients were included in the study of immunogenetic factors affecting the course of the disease (the study group was limited because 31 patients from the group died, and 48 patients did not wish to participate for various reasons). The patients were selected based on the following criteria: 1) confirmed case of parasitosis -positive serological finding and characteristic radiological findings (principally, ultrasound or computed tomography imaging data); 2) diagnosis occurred between the period of 1999 and 2015; 3) the patient had lived in Latvia for at least 15 years and was alive; 4) the patient gave their consent to participate in the study. We used the term "complicated" or severe course of the disease based on the following criteria: 1) echinococcosis lesion larger than 10 cm; 2) lesion count 5 or more; 3) inability to use radical treatment and 4) reoccurrence of disease after surgical removal of the parasite.
All patients participating in the study were divided into two groups based on subtype of the parasite -infection of Echinococcus granulosus and Echinococcus multilocularis, respectively 29 and 8 patients. Most of the patients (75%) were females. The mean age of females was 51.1 years and 55.4 years in males and was not significantly different between genders.
This study started in October 2015. Approval of the Rîga Stradiòð University (RSU) Ethics Committee was obtained to perform this study. Each participant signed an informed consent to participation and approval of the Central Medical Ethics Committee, Rîga, Latvia for the genetic analysis was also obtained.
Methods. HLA-DRB1
;-DQA1;-DQB1 typing detection was performed in the Joint Laboratory of Clinical Immunology and Immunogenetics of the Rîga Stradiòð University. For HLA Class II alleles detection, 4 ml of peripheral blood with EDTA were collected and stored at -20 o C before detection. For human DNA extraction QIAamp® DNA Blood Kit (Germany) was used in accordance with the methodology approved by the manufacturer.
Material from the data base of the Joint Laboratory of Clinical Immunology and Immunogenetics of RSU was used for the comparison of patient HLA test results with HLA of healthy blood donors (n = 100) determined in the laboratory. This control group included blood donors aged from 18 to 65 years, without HIV infection, viral hepatitis C and cytomegalovirus infection. No relatives were involved in this group. In both subsamples, clinical and control, the same protocol for DNA isolation and HLA typing was applied. The analysis was conducted in the Joint Laboratory of Clinical Immunology and Immunogenetics of RSU.
The investigation of HLA class II genotype of each patient was performed in the Joint Laboratory of Clinical Immunology and Immunogenetics of RSU. Peripheral blood samples (5 ml) were collected in EDTA containing tubes and stored at -20°C. The QIAamp® DNA Blood Kit (QIAGEN, Germany) was used for human DNA extraction according to manufacturer's instruction (Anonymous, 2016b) . DNA amplification was performed by Real-Time polymerase chain reaction (RT-PCR) with low resolution sequence specific primers (DNA-Technology, Russia) according to manufacturer's instructions (Anonymous, 2018 (Table 5 ).
In the HLA-DQA1 allele group, for alveolar echinococcosis patients we found that alleles *01:01 (OR = 1.89, p = 0.291) and *03:01 (OR = 1.48, p = 0.388) were more rare that in the control group and possibly protective but without statistical significance (Table 5) . 
T a b l e 1 PROTECTIVE AND RISK DRB1 ALLELES OF HLA CLASS II IN IN-PATIENTS WITH CYSTIC ECHINOCOCCOSIS (n = 29), ALVEOLAR ECHINOCOCCOSIS (n = 8) AND A CONTROL GROUP (n = 100) GROUPS Alleles
The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; ND, not defined; OR, odds ratio; CI, confidence interval; p-value (probability); **An extract cell value is less than 5, used Fisher extract results. The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; ND, not defined; OR, odds ratio; p-value (probability). The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; OR, odds ratio; p-value (probability). The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; ND, not defined; OR, odds ratio; CI, confidence interval; p-value (probability). **An extract cell value is less than 5, used Fisher extract results.
T a b l e 3 PROTECTIVE AND RISK DQB1 ALLELES OF HLA CLASS II IN IN-PATIENTS WITH CYSTIC ECHINOCOCCOSIS (n = 29), ALVEOLAR ECHINOCOCCOSIS (n = 8) AND A CONTROL GROUP (n = 100) GROUPS Alleles

T a b l e 5 PROTECTIVE AND RISK DQA1 ALLELES OF HLA CLASS II IN IN-PATIENTS WITH CYSTIC ECHINOCOCCOSIS (n = 29), ALVEOLAR ECHINOCOCCOSIS (n = 8) AND A CONTROL GROUP (n = 100) GROUPS Alleles
We found association of (Table 6) .
Regarding HLA-DRB1*/-DQB1*DQA1* genotypes, we found that Echinococcus infection in all groups was associated with the following genotypes: In further analysis, we found that in the cystic echinococcosis group, more severe presentation was associated with presence of the following genotypes: (Table 7) .
DISCUSSION
One of the objectives of the study was to determine HLA Class II allele occurrence among echinococcosis patients and their association with the severity of the disease. The literature data on the development of echinococcosis and immunogenetic factors of patients are limited. In the PubMed database only ten publications could be used, as some studies were not available in English or Russian, and some of the original publications could not be obtained. The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; OR, odds ratio; p-value (probability). The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; OR, odds ratio; p-value (probability).
The results showed that of HLA DRB1 gene alleles, *17:01 and *04:01 were more frequently found in patients with cystic echinococcosis. The association of allele *04:01 with increased risk of the disease has been described in China, but the Chinese publication refers to alveolar echinococcosis (Mosayebi et al., 2013) . Alleles *01:01 and *15:01 rarely occur among the patients in the cystic echinococcosis group. Similar observations on the protective action of allele *01:01 are mentioned in studies from Russia (Mosayebi et al., 2013) , Lebanon (Aydinli et al., 2007) , Saudi Arabia (Chakhtoura et al., 2007) and Turkey (Yalcin et al., 2010) . Alleles *17:01 and *11:01 occur more frequently in patients with alveolar echinococcosis. Contradictory data also exist: allele *11:01 in a study conducted in Germany was considered to be protective in the cases of alveolar echinococcosis (Eiermann et al., 1998) , similar data have been obtained in Turkey (Yalcin et al., 2010) , and studies conducted in different European countries suggest that it has a protective character in case of cystic echinococcosis (Lukmanova et al., 2011) . Allele *01:01 was identified as protective in the case of alveolar echinococcosis. It must be added that results similar to those in our study have been obtained from the nearest regions, for example, Europe or Russia, while partially differing data originate from Asian countries. These differences are potentially due to genetic differences in race.
Our study of HLA-DQB1 alleles indicated that allele *03:02 is significantly more frequent among cystic echinococcosis patients, and allele *03:01 in the alveolar echinococcosis patient group. These results contradict those in literature from Iran, where this allele was directly associated with a lower risk of cystic echinococcosis development (Mosayebi et al., 2013) , which could be explained by genetic differences.
The analysis of HLA-DQA1 alleles showed that allele *04:01 was significantly more frequent among cystic echinococcosis patients, while allele *01:01 was less common. No significant differences in allele frequency was found in the patient group with alveolar echinococcosis. The available literature lacked information on the association of alleles HLA-DQA1 with echinococcosis. The data obtained by us here could be used in similar studies in other Baltic States, as well as European Union countries, which could expand the data base used for the detection of similarities and differences.
In-depth analysis in the patient groups examined showed that the following haplotypes were associated with a more severe course of disease in the cystic echinococcosis group: HLA-DRB1 Immunogenetic data could prove significant for therapy planning in accordance with the individual characteristics of a patient, because no data on the optimum duration of therapy and whether the therapy can be terminated without facilitating the relapse of the infection are currently available. It is known that there are patients, in whom the disease is progressing slowly and does not create serious complications, but it must be kept in mind that there is a group of patients, in whom even a brief suspension of therapy can lead to a rapid increase in the activity of parasitic process. 
CONCLUSIONS
